title: Body mass index is a prognostic factor in adult patients with acute myeloid leukemia.
abstract: Body mass index (BMI), which represents the proportion of weight to height, is a controversial prognostic factor for acute myeloid leukemia (AML). We evaluated prognostic value of BMI in Japanese AML. The study included 369 adult patients with newly diagnosed AML who were administered either daunorubicin or idarubicin with cytarabine as induction chemotherapy. The patients were categorized into two groups according to their BMI: the NW group (BMI < 25.0 kg/m2; normal and underweight) and OW group (BMI ≥ 25.0 kg/m2; overweight and obese). We analyzed treatment efficacy and toxicity of induction chemotherapy, and survival outcomes in each group. Patients in the OW group showed a better complete remission rate than the NW group (86.1 versus 76.5%, P = 0.045), no early death (0.0 versus 4.1%, P = 0.042), and better overall survival (OS) at 3 years (62.2 versus 50.1%, P = 0.012). Multivariate analysis showed BMI is an independent prognostic factor for OS (hazard ratio 0.62, 95% confidence interval 0.42-0.92, P = 0.017). These results indicate the prognostic value of BMI in adult AML patients.
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Taiki
authors.initials: T
authors.lastname: Ando
authors.affiliation: Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan. etsukoy@yokohama-cu.ac.jp.|Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Kanagawa, Japan. etsukoy@yokohama-cu.ac.jp.
authors.forename: Etsuko
authors.initials: E
authors.lastname: Yamazaki
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Eriko
authors.initials: E
authors.lastname: Ogusa
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Ishii
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Wataru
authors.initials: W
authors.lastname: Yamamoto
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Motohashi
authors.affiliation: Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Tachibana
authors.affiliation: Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
authors.forename: Maki
authors.initials: M
authors.lastname: Hagihara
authors.affiliation: Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Matsumoto
authors.affiliation: Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Tanaka
authors.affiliation: Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan.
authors.forename: Chizuko
authors.initials: C
authors.lastname: Hashimoto
authors.affiliation: Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Koharazawa
authors.affiliation: Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
authors.forename: Katsumichi
authors.initials: K
authors.lastname: Fujimaki
authors.affiliation: Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Taguchi
authors.affiliation: Department of Hematology, Saiseikai Nanbu Hospital, Yokohama, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fujita
authors.affiliation: Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: Heiwa
authors.initials: H
authors.lastname: Kanamori
authors.affiliation: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Shin
authors.initials: S
authors.lastname: Fujisawa
authors.affiliation: Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Nakajima
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D015992:Body Mass Index; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D060828:Induction Chemotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin
keywords: Acute myeloid leukemia; Body mass index; Japanese; Obese